Celgene acquires EngMab
Celgene (NASDAQ: CELG) has bought Swiss biotech EngMab for USD 600 million. EngMab's focus is on T-cell bispecific antibodies (TCBs). TCBs bind simultaneously to a target on a tumor cell and to the T-cell receptor complex, leading...
Decision of the Swiss Federal Administrative Court (Bundesverwaltungsgericht) Concerning the Rates of University Hospitals
The Swiss Federal Administrative Court (Bundesverwaltungsgericht) decided on important issues concerning the calculation of payment rates of university hospitals. VISCHER (Andreas Albrecht and Michael Waldner) represented the...
Sale and lease-back of kneipp-hof's operating real estate
Credit Suisse Real Estate Fund LivingPlus (CS REF LivingPlus) acquires all operating real estate from kneipp-hof Dussnang which leases the operating real estate back. The VISCHER Team, led by Benedict F. Christ (partner...
Vamed acquires kneipp-hof Dussnang AG
The international health care Provider VAMED (part of the German Fresenius group) extends its Swiss activities and acquires 100 percent of kneipp-hof Dussnang AG. This allows the seller, Kloster Heiligkreuz of Cham, to implement a...
Sonetik closes financing to fund further growth in the US
VISCHER advises Sonetik in a financing to fund further growth in the US. The participants in this Series A2 financing include existing investors, BB Biotech Ventures, and new investors joining the consortium, Aeris Capital. The...
Displaying results 11 to 15 out of 15
- « Previous
- 1
- 2